Breakthrough trial tests first medicine targeting Autism's core challenges

NCT ID NCT06333964

Summary

This large, completed study tested whether a new medicine called AST-001 could improve the core social and behavioral challenges of autism in children. It involved 169 children in Korea and compared the medicine to a placebo. The goal was to see if this treatment could help where no other approved medicines currently exist for autism's main symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Hallym University Medical Center

    Anyang-si, Gyeonggi-do, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

  • Koera University Guro Hospital

    Seoul, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, South Korea

  • Samsung Changwon Medical Center

    Changwon, Gyeongsangnam-do, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Soon Chun Hyang University Hospital Cheonan

    Cheonan, Chungcheongnam-do, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.